Deva Holding AS (DEVA) Stock Price & News

DEVA:IST

Deva Holding AS

TRY 65.35

-1.06%

(-0.70) 1D

Jun 5, 6:10:00 PM GMT+3 · TRY

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for DEVA...

Open

TRY 66.40

High

TRY 66.60

Low

TRY 65.15

Mkt. cap

13.07B

Avg. vol.

694.53K

Volume

267.75K

52-wk high

TRY 81.75

52-wk low

TRY 51.00

EPS

-TRY 4.78

Shares outstanding

200.02M

No. of employees

Open

TRY 66.40

High

TRY 66.60

Low

TRY 65.15

Mkt. cap

13.07B

Avg. vol.

694.53K

Volume

267.75K

52-wk high

TRY 81.75

52-wk low

TRY 51.00

EPS

-TRY 4.78

Shares outstanding

200.02M

No. of employees

Related stocks

BIM Birlesik Magazalar AS

TRY 377.25

+1.14%

MEDTR

Meditera Tibbi Mlzm Sny Tcrt AS

TRY 29.96

-0.40%

TRILC

Turk Ilac Ve Serum Sanayi AS

TRY 2.00

-9.91%

News stories

From sources across the web

Simply Wall Street

48 minutes ago

Marvell Joins S&P 500 As AI Data Center Expectations Stretch Valuation

Moomoo

1 hour ago

Wall Street Snaps Nine-Week Rally As Tech Rout Batters Stocks

Insider Monkey

43 minutes ago

10 Best Big Company Stocks to Buy Right Now

MarketWatch

3 hours ago

S&P 500 sees $1.8 trillion wipeout, Nasdaq tallies biggest point drop on record: What investors need to know about Friday’s selloff

Profile

DEVA Holding A.Ş. is a leading Turkish pharmaceutical company founded in 1958. As of 2024, it ranked 3rd in unit sales and 6th in TL sales in Turkey’s pharmaceutical market. The company operates three EU GMP- and US FDA-approved facilities in Çerkezköy and Kartepe, with an annual production capacity of 620 million units. DEVA’s portfolio covers 10 therapeutic areas, including cardiovascular, dermatology, ophthalmology, hematology, and anti-infectives, and includes 1,404 registered products across 82 countries. Recognized as Turkey’s top pharmaceutical company in R&D spending by Turkishtime’s 2024 R&D 250 Report, DEVA employs over 500 researchers and 3,000 staff in total. Guided by sustainability and innovation, the company focuses on developing accessible, effective, and environmentally responsible healthcare solutions for both domestic and global markets. Wikipedia

About Deva Holding AS

CEO-

Employees3.04K

FoundedSep 22, 1958

Headquarters-

SectorPharmaceutical industry

Websitedeva.com.tr

All values in TRY	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	4.84B	4.47B	5.49B	5.91B
Cost of goods sold	3.29B	3.02B	3.84B	3.83B
Cost of revenue	3.29B	3.02B	3.84B	3.83B
Research and development expenses	283.92M	264.29M	174.34M	338.10M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.39B	1.30B	1.58B	1.50B
Operating expense	1.64B	1.55B	1.74B	1.80B
Total operating expenses	4.93B	4.58B	5.58B	5.63B
Operating income	-88.02M	-102.14M	-89.10M	278.24M
Other non operating income	808.89M	337.87M	185.09M	617.53M
EBT including unusual items	197.34M	-137.34M	-340.89M	547.01M
EBT excluding unusual items	205.01M	-137.34M	-362.51M	548.03M
Income tax expense	-340.99M	-116.52M	1.00B	637.90M
Effective tax rate	-172.79%	84.84%	-294.28%	116.62%
Other operating expenses	-38.46M	-9.80M	-11.48M	-36.46M
Net income	538.34M	-20.81M	-1.34B	-90.89M
Net profit margin	11.12%	-0.47%	-24.48%	-1.54%
Earnings per share	-	-	-	-
Interest and investment income	159.53M	59.54M	23.47M	105.21M
Interest expense	-802.12M	-617.63M	-656.70M	-506.82M
Net interest expenses	-642.59M	-558.09M	-633.23M	-401.62M
Depreciation and amortization charges	-	-	-	-
EBITDA	183.35M	237.92M	622.26M	686.52M
Gain or loss from assets sale	-12.26M	-15.06M	-15.93M	-32.28M

AI content may include mistakes. Learn more

HelpSend feedbackPrivacy Terms Disclaimer

Finance

Research